

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A candesartan cilexetil 1,4-dioxane solvate, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.0, 10.7, 16.2, 18.0, 19.7, 20.6, 21.3, 21.7, and 22.3 degrees.
2. (Previously Presented): The candesartan cilexetil 1,4-dioxane solvate of claim 1, wherein the content of 1,4-dioxane is 8.8 to 13.0 % w/w.
3. (Canceled)
4. (Currently Amended): Candesartan cilexetil 1,4-dioxane solvate of claim 3 1, further characterized by an x-ray powder diffraction pattern as in figure 1.
5. (Previously Presented): The process for the preparation of candesartan cilexetil 1,4-dioxane solvate of claim 1, which comprises:
 - a) dissolving candesartan cilexetil in 1,4-dioxane; and
 - b) crystallizing candesartan cilexetil as 1,4-dioxane solvate from the solution at 5°C to 15°C.
6. (Previously Presented): The process according to claim 5, wherein candesartan cilexetil used is a crystalline form of candesartan cilexetil.
7. (Previously Presented): The process according to claim 6, wherein the crystalline form of candesartan cilexetil is candesartan cilexetil form III.
8. (Original): A crystalline candesartan cilexetil form III, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.3, 7.3, 8.1, 8.9, 10.1, 14.6, 15.0, 15.8, and 18.8 degrees.
9. (Original): Candesartan cilexetil form III of claim 8, further characterized by an x-ray powder diffraction pattern as in figure 2.
10. (Previously Presented): The process for the preparation of candesartan cilexetil form III of claim 8, which comprises:
 - a) mixing candesartan cilexetil with toluene;
 - b) heating to obtain clear solution;

Application No. 10/509,141
Amendment Dated 11/12/2008
Reply to Office Action of 06/04/2008

- c) cooling slowly to 0°C to 5°C in about 1 hour;
- d) maintaining at 0°C to 5°C for about 1 hour; and
- e) filtering the separated solid.

11. (Previously Presented): The process according to claim 10, wherein candesartan cilexetil used is candesartan cilexetil as 1,4-dioxane solvate of claim 1.

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)